BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15148985)

  • 1. Industrial interests versus public health: the gap is growing.
    Prescrire Int; 2004 Apr; 13(70):71-6. PubMed ID: 15148985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 3. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A; Martin P
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 7. Packaging of pharmaceuticals: still too many dangers but several encouraging initiatives.
    Prescrire Int; 2007 Jun; 16(89):126-8. PubMed ID: 17585428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Future challenges and prospects for drug companies].
    Lajoux C
    Bull Acad Natl Med; 2008 Apr; 192(4):623-30; discussion 630-2. PubMed ID: 19024935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Big pharma and health care: unsolvable conflict of interests between private enterprise and public health.
    Brezis M
    Isr J Psychiatry Relat Sci; 2008; 45(2):83-9; discussion 90-4. PubMed ID: 18982834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drugs and indications in 2011. France is better focused on patients' interests after the Mediator scandal, but stagnation elsewhere.
    Prescrire Int; 2012 Apr; 21(126):106-10. PubMed ID: 22515141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Better medicines for children].
    Brasseur D
    Rev Med Brux; 2006; 27 Spec No():Sp25-8. PubMed ID: 21818889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Draft EU regulation on paediatric medicines: some improvements but still far from perfect.
    Prescrire Int; 2006 Feb; 15(81):32-3. PubMed ID: 16548115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fake drugs, what are we talking about? Counterfeit drugs, informal market, quality of pharmaceutical… Thought from an anthropological study led in Benin].
    Baxerres C
    Bull Soc Pathol Exot; 2014 May; 107(2):121-6. PubMed ID: 24639135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of new drugs and indications in 2002: financial speculation or better patent care?
    Prescrire Int; 2003 Apr; 12(64):74-7. PubMed ID: 12674131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Public health benefits of non prescription medicines and self care].
    Baumelou A
    Bull Acad Natl Med; 2007 Nov; 191(8):1527-31. PubMed ID: 18666454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Charter of medicines promotion and rational use by physicians].
    Baumevieille M; Bégaud B; Maurain C
    Therapie; 2007; 62(1):39-44. PubMed ID: 17374346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.